Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin’s lymphoma and characterization of the loss of the target antigen

Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin’s lymphoma and characterization of the loss of the target antigen

Background Infusion of T cells modified with a chimeric antigen receptor (CAR) targeting CD19 has achieved exceptional responses in patients with non-Hodgkin’s lymphoma (NHL), which led to the approval of CAR targeting CD19 (CART19) (Axi-cel and Liso-cel) as second line of treatment for adult patien...

Full description

Saved in:
Bibliographic Details
Main Authors: Manel Juan, Beatriz Martín-Antonio, Pablo Engel, Narcis Fernandez-Fuentes, Esperanza Esquinas, Alvaro Moreno-Sanz, Victor Sandá, Damian Stodulski-Ciesla, Jennifer Borregón, Virginia Peña-Blanque, Javier Fernández-Calles, Juana Serrano-Lopez, Pilar Llamas-Sillero, Laura Solán-Blanco
Format: Article
Language:English
Published: BMJ Publishing Group 2024-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/12/e009485.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/12/e009485.full

Similar Items